| Project/Area Number |
23K27555
|
|---|
| Project/Area Number (Other) |
23H02864 (2023)
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Multi-year Fund (2024)
Single-year Grants (2023) |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52040:Radiological sciences-related
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
織内 昇 福島県立医科大学, 公私立大学の部局等, 教授 (40292586)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
関亦 明子 福島県立医科大学, 看護学部, 教授 (50321823)
小島 祥敬 福島県立医科大学, 医学部, 教授 (60305539)
右近 直之 福島県立医科大学, 公私立大学の部局等, 講師 (70792985)
趙 松吉 福島県立医科大学, 公私立大学の部局等, 教授 (80374239)
|
|---|
| Project Period (FY) |
2024-04-01 – 2026-03-31
|
| Project Status |
Granted (Fiscal Year 2024)
|
| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2025: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2024: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2023: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Keywords | aargeted α therapy / 211At-PSMA / radiation sialadenitis / salivary gland / prostate cancer / xerostomia / radionuclide therapy / 核医学治療 / アスタチン211 / 唾液腺 / PSMA / 前立腺癌 / targeted α therapy / SNARE proteins |
|---|
| Outline of Research at the Start |
The goal of this study is to elucidate the mechanism of salivary gland uptake of 211At-labeled compounds from a molecular perspective by clarifying the mechanism in relation to receptors such as the involvement of SNARE proteins, and to develop treatment for xerostomia.
|
| Outline of Annual Research Achievements |
The goal of this study was to elucidate the mechanism of salivary gland uptake of 211At-labeled compounds, and to develop a treatment for xerostomia caused by salivary gland disorders.
By evaluating the specific uptake of the 211At-PSMA ligand into the salivary glands of normal mice, we clarify the molecular mechanism of uptake in relation to receptors such as the involvement of SNARE proteins, and obtain knowledge that leads to the treatment of salivary gland disorders, including xerostomia.
We quantitatively evaluated the uptake of 211At-PSMA ligand into the salivary glands and other organs of normal mice and clarified the biodistribution of 211At-PSMA ligand. The molecular mechanism of 211At-PSMA ligand uptake will lead to the treatment of salivary gland disorders.
|
| Current Status of Research Progress |
Current Status of Research Progress
3: Progress in research has been slightly delayed.
Reason
We quantitatively evaluated the uptake of 211At-PSMA ligand into the salivary glands of normal mice and intended to clarify the molecular mechanism of 211At-PSMA ligand uptake in relation to receptors such as the involvement of SNARE proteins and obtain knowledge that will lead to the treatment of salivary gland disorders.
The 211At-PSMA ligand is administered to normal mice, and the removed salivary glands as well as major organs are analyzed to quantitate the absorbed dose of the salivary glands and other organs. The relationship between the absorbed dose estimated from the accumulation of 211At-PSMA ligands and the amount of salivation was not clarified.
|
| Strategy for Future Research Activity |
We are planning studies to clarify the mechanism by which 211At-PSMA ligands accumulate in the salivary glands by elucidating a molecule involved in the transport and receptor binding of 211At-PSMA ligands by inhibiting uptake by knockdown of the molecules in the salivary glands, and to develop a preventive method for radiation sialadenitis.
|
